SLBST Pharma Inc.

slbst pharma is a clinical-stage drug development company that is re-purposing hydroxychloroquine (hcq) as the first non-hormonal, long-term therapy for endometriosis. slbst holds exclusive worldwide rights to issued patents in the us and europe for “administering hcq to patients in an amount effective to treat endometriosis”. the company has solid pre-clinical data suggesting the benefits of hcq. in a mouse model of endometriosis, hcq decreased the number of lesions by 60%, while reducing glandular components in the remaining lesions. the same 2016 study reported that hcq exposure greatly reduced the survival of human endometriotic cells in vitro. two recent clinical, observational studies provide further support to this thesis. a 2018 study at cleveland clinic showed that women with endometriosis, who incidentally happen to be taking hcq (or other dmards), have decreased opioid usage. in 2021, a large taiwanese study in women with newly diagnosed lupus (sle) reported that treatm